Breaking: Cellectar Biosciences Inc on Focus After Crashing In Today’s Session

Breaking: Cellectar Biosciences Inc on Focus After Crashing In Today's Session

The stock of Cellectar Biosciences Inc (NASDAQ:CLRB) is a huge mover today! About 146,426 shares traded hands. Cellectar Biosciences Inc (NASDAQ:CLRB) has risen 22.54% since April 18, 2016 and is uptrending. It has outperformed by 18.11% the S&P500.
The move comes after 7 months negative chart setup for the $12.58M company. It was reported on Nov, 18 by Barchart.com. We have $2.14 PT which if reached, will make NASDAQ:CLRB worth $1.26 million less.

According to Zacks Investment Research, “Cellectar Biosciences, Inc. is developing agents to detect, treat and monitor a broad spectrum of cancers. It uses a novel phospholipid ether platform technology as a targeted delivery and retention vehicle. Cellectar Biosciences Inc., formerly known as Novelos Therapeutics, Inc., is headquartered in Madison, Wisconsin.”

More notable recent Cellectar Biosciences Inc (NASDAQ:CLRB) news were published by: Reuters.com which released: “BRIEF-Cellectar Biosciences Inc Q3 loss from operations was $2.5 million” on November 11, 2016, also Marketwatch.com with their article: “/quotes/zigman/3870025/realtime” published on February 24, 2014, Seekingalpha.com published: “Cellectar Biosciences Readies New Offering As Trials Advance” on November 10, 2016. More interesting news about Cellectar Biosciences Inc (NASDAQ:CLRB) were released by: Finance.Yahoo.com and their article: “Cellectar Biosciences to Present at the LD Micro Invitational” published on June 02, 2016 as well as Globenewswire.com‘s news article titled: “Cellectar Biosciences To Present at the 18th Annual Rodman & Renshaw Global …” with publication date: September 06, 2016.

CLRB Company Profile

Cellectar Biosciences, Inc., formerly Novelos Therapeutics, Inc., incorporated on June 24, 1996, is a clinical stage biopharmaceutical company. The Firm is engaged in developing phospholipid ether-drug conjugates (PDCs) for the treatment and diagnostic imaging of cancer. The Company’s research and development program is based on its PDC cancer targeting delivery platform. The Company’s platform helps in discovery and development of a range of cancer targeting agents. The Company’s pipeline consists of pre-clinical and clinical product candidates, including radiotherapeutic and chemotherapeutic PDC’s. The Company’s PDC product portfolio includes CLR 131, CLR 125, CLR 124, CLR 1502 and CTX Product Portfolio.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Tags: , ,

Related posts

Leave a Comment